Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice

被引:33
作者
Borner, C
Wadl, HS
Fellay, I
Selzer, E
Polterauer, P
Jansen, B
机构
[1] Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol Mol Pharmacol, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Radiat Therapy, A-1090 Vienna, Austria
[4] Univ Vienna, Dept Surg, Div Vasc Surg, A-1090 Vienna, Austria
[5] Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland
关键词
Bak; Bax; Bcl-2; Bcl-x(L); chemoresistance; melanoma; N-ras;
D O I
10.1097/00008390-199908000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of the N-ras gene by point mutation occurs in about 15% of all human melanomas, In recently established severe combined immunodeficiency (SCID) mouse xenotransplantation models for human melanoma, we demonstrated that mutated N-ras not only contributes to tumour growth by enhancing cellular proliferation, but also by blocking apoptosis, Mutated N-ras overexpression protected human melanomas from naturally occurring apoptosis and, in a more pronounced way, from chemotherapy-induced apoptosis in vitro and in vivo. Given the potential clinical importance of these findings we sought to determine the underlying mechanism. We found that mutated N-ras specifically upregulates the expression of the anti-apoptosis gene bcl-2 in two human melanoma cell lines in vitro and in SCID mice. Neither the expression of the anti-apoptotic protein Bcl-x(L) nor that of the pro-apoptotic proteins Bax and Bak were altered in cells expressing mutated N-Ras. The increase in Bcl-2 expression mediated by mutated res therefore qualifies as a rational explanation for the enhanced chemoresistance of human melanoma expressing mutated N-Ras. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:347 / 350
页数:4
相关论文
共 20 条
[1]  
CHEN CY, 1995, ONCOGENE, V11, P1487
[2]   Phosphorylation of Bcl-2 protein and association with p21(Ras) in Ras-induced apoptosis [J].
Chen, CY ;
Faller, DV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (05) :2376-2379
[3]   DRUG-TARGET INTERACTIONS - ONLY THE 1ST STEP IN THE COMMITMENT TO A PROGRAMMED CELL-DEATH [J].
DIVE, C ;
HICKMAN, JA .
BRITISH JOURNAL OF CANCER, 1991, 64 (01) :192-196
[4]   Ras signalling and apoptosis [J].
Downward, J .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) :49-54
[5]  
FERNANDEZ A, 1994, ONCOGENE, V9, P2009
[6]  
FOUNTAIN JW, 1998, CUTANEOUS MELANOMA, P475
[7]  
Jansen B, 1996, INT J CANCER, V67, P821, DOI 10.1002/(SICI)1097-0215(19960917)67:6<821::AID-IJC11>3.0.CO
[8]  
2-4
[9]  
Jansen B, 1997, CANCER RES, V57, P362
[10]   bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice [J].
Jansen, B ;
Schlagbauer-Wadl, H ;
Brown, BD ;
Bryan, RN ;
van Elsas, A ;
Müller, M ;
Wolff, K ;
Eichler, HG ;
Pehamberger, H .
NATURE MEDICINE, 1998, 4 (02) :232-234